Abstract
Alzheimers disease is a devastating degenerative disorder for which there is no cure or effective treatment. Although the etiology of Alzheimers disease is not fully understood, compelling evidence indicates that deposition of aggregates composed by a misfolded form of the amyloid beta peptide (Aβ) is the central event in the disease pathogenesis. Therefore, an attractive therapeutic strategy is to prevent or reverse Aβ misfolding and aggregation. Diverse strategies have been described to identify inhibitors of this process, including screening of libraries of small molecules chemical compounds, rational design of synthetic peptides, assessment of natural Aβ-binding proteins and stimulation of the immune system by vaccination. In this article we describe these different approaches, their principles and their potential strengths and weaknesses. Overall the available data suggest that the development of drugs to interfere with Aβ misfolding and aggregation is a feasible target that hold great promise for the treatment of Alzheimers disease.
Keywords: Aggregation inhibitors, β-sheet breakers, amyloid, Alzheimer's disease
Current Topics in Medicinal Chemistry
Title: Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Volume: 7 Issue: 1
Author(s): L. D. Estrada and C. Soto
Affiliation:
Keywords: Aggregation inhibitors, β-sheet breakers, amyloid, Alzheimer's disease
Abstract: Alzheimers disease is a devastating degenerative disorder for which there is no cure or effective treatment. Although the etiology of Alzheimers disease is not fully understood, compelling evidence indicates that deposition of aggregates composed by a misfolded form of the amyloid beta peptide (Aβ) is the central event in the disease pathogenesis. Therefore, an attractive therapeutic strategy is to prevent or reverse Aβ misfolding and aggregation. Diverse strategies have been described to identify inhibitors of this process, including screening of libraries of small molecules chemical compounds, rational design of synthetic peptides, assessment of natural Aβ-binding proteins and stimulation of the immune system by vaccination. In this article we describe these different approaches, their principles and their potential strengths and weaknesses. Overall the available data suggest that the development of drugs to interfere with Aβ misfolding and aggregation is a feasible target that hold great promise for the treatment of Alzheimers disease.
Export Options
About this article
Cite this article as:
Estrada D. L. and Soto C., Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment, Current Topics in Medicinal Chemistry 2007; 7 (1) . https://dx.doi.org/10.2174/156802607779318262
DOI https://dx.doi.org/10.2174/156802607779318262 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNAs and Peroxisome Proliferator-Activated Receptors Governing the Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Echocardiogram versus Cardiac Magnetic Resonance Imaging for the Diagnosis of Non-compaction Cardiomyopathy – A Case Report
New Emirates Medical Journal Cardiac Chamber Volumetric Assessment Using 3D Ultrasound - A Review
Current Pharmaceutical Design Pharmacokinetics of Antifungal Agents in Neonates and Young Infants
Current Medicinal Chemistry Focal Adhesion Kinase: From In Vitro Studies to Functional Analyses In Vivo
Current Protein & Peptide Science COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention and Treatment of COVID-19
Current Medicinal Chemistry Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews Genetics of Ion Channels in Sudden Unexplained Death Syndrome: Moving Beyond Idiopathic Reactions To Personalized Risk Assessment
Current Pharmacogenomics and Personalized Medicine Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients
Current Cancer Therapy Reviews Biomarker Assays for Personalised Stroke Risk Assessment in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets The Shift in the “Paradigm” of the Pharmacology of Hypertension
Current Topics in Medicinal Chemistry MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches
Current Pharmaceutical Design Genetics of Primary CoQ10 Deficiency
Current Genomics Transient Receptor Potential (TRP) Channels and Cardiac Fibrosis
Current Topics in Medicinal Chemistry Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets
Current Pharmaceutical Design Stage A: Can Heart Failure Be Prevented?
Current Cardiology Reviews Left Ventricular Non-compaction: From Recognition to Treatment
Current Pharmaceutical Design Cardiosphere-derived Progenitor Cells for Myocardial Repair Following Myocardial Infarction
Current Pharmaceutical Design Regulative Roles of Ghrelin in Ingestive Behavior, Upper Gastrointestinal Motility, and Secretion
Current Nutrition & Food Science